Development of FVIII-neutralizing antibodies (inhibitors) is one of the main complications occurring in 30% of severe hemophilia A (HA) patients undergoing replacement therapy. Both lack of central tolerance, due to the congenital absence of FVIII, and the presence of danger signals are factors involved in inhibitors development, which is definitely related to the immune cells activation. Since recent studies have been proposing new extra-coagulative roles for FVIII in the immuno-hematological biology and have shown the presence of increased levels of several inflammatory cytokines in untreated HA patients, we sought to investigate the effect of FVIII absence on the immune cell populations before and after challenge with a specific (...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
AbstractAnti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for...
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hem...
Development of FVIII-neutralizing antibodies (inhibitors) is one of the main complications occurring...
Despite the clinical relevance of anti-factor VIII (FVIII) antibodies (anti-FVIII inhibitors) impair...
The development of neutralizing antibodies against factor VIII (FVIII), so called ‘inhibitors’, is o...
Memory B cells are responsible for the rapidly emerging antibody response after antigen reexposure. ...
Hemophilia A is a clotting disorder caused by functional factor VIII (FVIII) deficiency. About 25% o...
Essentials Initial immune cell interactions leading to factor (F) VIII immunity are not well charact...
Immune responses directed against clotting factor FVIII (FVIII) seriously complicate treatments for ...
International audienceHemophilia A (HA) is an X-linked inherited disorder caused by a defect in the ...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
Coagulation Factor VIII (FVIII) replacement therapy in hemophilia A patients is complicated by the d...
International audienceINTRODUCTION:Approximately, 25% of haemophilia A (HA) patients treated by fact...
Anti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for hemophi...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
AbstractAnti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for...
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hem...
Development of FVIII-neutralizing antibodies (inhibitors) is one of the main complications occurring...
Despite the clinical relevance of anti-factor VIII (FVIII) antibodies (anti-FVIII inhibitors) impair...
The development of neutralizing antibodies against factor VIII (FVIII), so called ‘inhibitors’, is o...
Memory B cells are responsible for the rapidly emerging antibody response after antigen reexposure. ...
Hemophilia A is a clotting disorder caused by functional factor VIII (FVIII) deficiency. About 25% o...
Essentials Initial immune cell interactions leading to factor (F) VIII immunity are not well charact...
Immune responses directed against clotting factor FVIII (FVIII) seriously complicate treatments for ...
International audienceHemophilia A (HA) is an X-linked inherited disorder caused by a defect in the ...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
Coagulation Factor VIII (FVIII) replacement therapy in hemophilia A patients is complicated by the d...
International audienceINTRODUCTION:Approximately, 25% of haemophilia A (HA) patients treated by fact...
Anti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for hemophi...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
AbstractAnti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for...
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hem...